Le-Ping Fang1, Xiao-Yan Xu1, Yu Ji1, Pu-Wen Huang2. 1. Department of Oncology, the First Affiliated Hospital of Nanjing Medical University, No. 300, GuangzhouRoud, GuLou District, Nanjing City, 210000, Jiangsu Province, China. 2. Department of Oncology, the First Affiliated Hospital of Nanjing Medical University, No. 300, GuangzhouRoud, GuLou District, Nanjing City, 210000, Jiangsu Province, China. huangpuwen@hotmail.com.
Abstract
PURPOSE: This research aims to analyze neutrophil-to-lymphocyte ratio (NLR) for resectable pancreatic ductal adenocarcinoma (PDAC) patients and reveal its predictive value. METHODS: We enrolled 389 pancreatic adenocarcinoma patients who had undergone curative surgery between January 1, 2008 and August 15, 2015 in Jiangsu Provincial People's Hospital, and they were followed up until December 20, 2016. Among them, 219 patients had definite recurrence record in our hospital. The appropriate cutoff value for the NLR was obtained from X-tile software. The association between qualitative variables and NLR was analyzed by Chi-square test or Fisher's exact test, and for quantitative values, the association was analyzed by independent Student's t test. Additionally, survival analysis was performed by Kaplan-Meier plots. Independent prognostic factors were found according to Cox regression analysis. RESULTS: Based on univariate analysis, the elevated preoperative NLR had an important influence on the decreased recurrence-free survival (RFS) (8.2 vs. 14.9 months) and overall survival (OS) (13.7 vs. 22 months), and this result also counted in the multivariate analysis. Regarding OS, both patients with or without postoperative chemotherapy can obtain benefits from low NLR according to subgroup analysis. Stage I and II pancreatic adenocarcinoma patients can get longer OS and RFS from low NLR, while patients with stage III cancer cannot. Regarding recurrence site, high NLR level was also related to distant metastasis (P = 0.02). CONCLUSION: Preoperative NLR level could be a useful prognostic indication for resectable pancreatic adenocarcinoma patients.
PURPOSE: This research aims to analyze neutrophil-to-lymphocyte ratio (NLR) for resectable pancreatic ductal adenocarcinoma (PDAC) patients and reveal its predictive value. METHODS: We enrolled 389 pancreatic adenocarcinomapatients who had undergone curative surgery between January 1, 2008 and August 15, 2015 in Jiangsu Provincial People's Hospital, and they were followed up until December 20, 2016. Among them, 219 patients had definite recurrence record in our hospital. The appropriate cutoff value for the NLR was obtained from X-tile software. The association between qualitative variables and NLR was analyzed by Chi-square test or Fisher's exact test, and for quantitative values, the association was analyzed by independent Student's t test. Additionally, survival analysis was performed by Kaplan-Meier plots. Independent prognostic factors were found according to Cox regression analysis. RESULTS: Based on univariate analysis, the elevated preoperative NLR had an important influence on the decreased recurrence-free survival (RFS) (8.2 vs. 14.9 months) and overall survival (OS) (13.7 vs. 22 months), and this result also counted in the multivariate analysis. Regarding OS, both patients with or without postoperative chemotherapy can obtain benefits from low NLR according to subgroup analysis. Stage I and II pancreatic adenocarcinomapatients can get longer OS and RFS from low NLR, while patients with stage III cancer cannot. Regarding recurrence site, high NLR level was also related to distant metastasis (P = 0.02). CONCLUSION: Preoperative NLR level could be a useful prognostic indication for resectable pancreatic adenocarcinomapatients.
Authors: Georgios Gemenetzis; Fabio Bagante; James F Griffin; Neda Rezaee; Ammar A Javed; Lindsey L Manos; Anne M Lennon; Laura D Wood; Ralph H Hruban; Lei Zheng; Atif Zaheer; Elliot K Fishman; Nita Ahuja; John L Cameron; Matthew J Weiss; Jin He; Christopher L Wolfgang Journal: Ann Surg Date: 2017-08 Impact factor: 12.969
Authors: Alok A Khorana; Pamela B Mangu; Jordan Berlin; Anitra Engebretson; Theodore S Hong; Anirban Maitra; Supriya G Mohile; Matthew Mumber; Richard Schulick; Marc Shapiro; Susan Urba; Herbert J Zeh; Matthew H G Katz Journal: J Clin Oncol Date: 2016-05-31 Impact factor: 44.544
Authors: Lauren A Licata; Cang T Nguyen; Rachel A Burga; Vincent Falanga; N Joseph Espat; Alfred Ayala; Mitchell Thorn; Richard P Junghans; Steven C Katz Journal: J Leukoc Biol Date: 2013-07-24 Impact factor: 4.962
Authors: A McGarry Houghton; Danuta M Rzymkiewicz; Hongbin Ji; Alyssa D Gregory; Eduardo E Egea; Heather E Metz; Donna B Stolz; Stephanie R Land; Luiz A Marconcini; Corrine R Kliment; Kimberly M Jenkins; Keith A Beaulieu; Majd Mouded; Stuart J Frank; Kwok K Wong; Steven D Shapiro Journal: Nat Med Date: 2010-01-17 Impact factor: 53.440
Authors: Daniella Karassawa Zanoni; Cristina Valero; Marlena R McGill; Pablo H Montero; Jatin P Shah; Richard J Wong; Ian Ganly; Snehal G Patel Journal: Oral Oncol Date: 2021-12-01 Impact factor: 5.972